Date:3/26/2009

based on Thoratec's current expectations, estimates, forecasts and projections. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: Failure of HeartWare's stockholders to approve the proposed transaction; the challenges and costs of closing, integrating, restructuring and achieving anticipated synergies; the ability to retain key employees; and other economic, business, competitive, and/or regulatory factors affecting the businesses of Thoratec and HeartWare generally, including those set forth in the filings of Thoratec and HeartWare with the Securities and Exchange Commission (the "SEC"), especially in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of their respective annual reports on Form 10-K and quarterly reports on Form 10-Q, their current reports on Form 8-K and other SEC filings. These forward-looking statements speak only as of the date hereof. Thoratec undertakes no obligation to publicly release the results of any revisions or updates to these forward-looking statements that may be made to reflect events or circumstances after the date hereof, or to reflect the occurrence of unanticipated events.

Additional Information and Where You Can Find It

Thoratec will file a Registration Statement on Form S-4 containing a proxy statement/prospectus and other documents concerning the proposed acquisition and HeartWare will file a proxy statement and other documents concerning the acquisition, in each case with the SEC. Investors are urged to read the proxy statement/prospectus when it becomes available and other relevant documents filed with the SEC because they will contain important information. Security holders may obtain a free copy of the proxy statement/prospectus (when it is available) and other documents filed by Thoratec and HeartWare with the SEC at
'/>"/>

SOURCE Thoratec Corporation Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related medicine news :

1. Thoratec Presentation at Raymond James Conference to Be Webcast
2. Thoratec Announces Definitive Agreement to Acquire HeartWare International For US$282 Million;
3. Thoratec Reports 34 Percent Increase in 2008 Revenues
4. Thoratec Schedules Fiscal 2008 Year-End Conference Call, Webcast
5. Thoratec Presentation at Piper Jaffary Conference to be Webcast
6. Thoratec Reports 44 Percent Increase in Second Quarter Revenues;
7. Thoratec Schedules Second Quarter 2008 Conference Call, Webcast
8. Thoratec Schedules First Quarter 2008 Conference Call, Webcast
9. Thoratec Announces Unanimous FDA Advisory Panel Recommendation for Approval of HeartMate II(R) for Bridge-to-Transplantation
10. URGENT Thoratec Corporation Worldwide Recall of Implantable Ventricular Assist Device
11. Thoratecs ITC Division Receives FDA Warning Letter